Baseline serum uric acid level is associated with progression-free survival, disease control rate, and safety in postoperative patients with colorectal cancer treated by FOLFOX, FOLFIRI, or XELOX

Baseline serum uric acid level is associated with progression-free survival, disease control rate, and safety in postoperative patients with colorectal cancer treated by FOLFOX, FOLFIRI, or XELOX

BackgroundHigh serum uric acid (SUA) levels increase the risk of overall cancer morbidity and mortality, particularly for digestive malignancies. Nevertheless, the correlation between SUA level and clinical outcomes of the postoperative patients with colorectal cancer (CRC) treated by chemotherapy i...

Full description

Bibliographic Details
Main Authors: Xi Zhang, Qing-hong Chen, Ying Yang, Jing-xin Lin, Yan-chun Li, Tian-yu Zhong, Jie Chen, Si-qi Wu, Xiao-hu Chen, Rui-si Zhou, Jia-man Lin, Dong-qing Wang, Qiu-xing He, Yan-ting You, Xing-hong Zhou, Qiang Zuo, Yan-yan Liu, Jing-ru Cheng, Yi-fen Wu, Xiao-shan Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Oncology
Subjects:
uric acid
colorectal cancer
prognosis
disease control rate
safety
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.918088/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.918088/full

Similar Items